Phase I trial of MVA-BN RSV
Latest Information Update: 25 Jul 2023
Price :
$35 *
At a glance
- Drugs MVA-BN RSV (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- 22 Jul 2023 Status changed from planning to withdrawn prior to enrolment according to Bavarian Nordic media release.
- 26 Apr 2022 New trial record